Education
About Us
Working with TipRanks
Follow Us
Acurx Pharmaceuticals (ACXP)
NASDAQ:ACXP
ACXP Stock Chart & Stats
$4.11
-$0.07(-8.37%)
At close: 4:00 PM EST
$4.11
-$0.07(-8.37%)
Day’s Range― - ―
52-Week Range$3.17 - $25.00
Previous CloseN/A
Volume243.54K
Average Volume (3M)1.14M
Market Cap
$10.03M
Enterprise Value$6.10M
Total Cash (Recent Filing)$5.91B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Mar 12, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding2,081,323
10 Day Avg. Volume3,231,033
30 Day Avg. Volume1,135,368
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)22.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.34
Enterprise Value/Market Cap0.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.49
Forecast
1Y Price Target
$30.50Price Target Upside642.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyIbezapolstat demonstrated encouraging clinical efficacy in a Phase 2a/b study, showing success in treating C. diff infection with a high clinical cure rate.
Microbiome SelectivityIbezapolstat is further differentiated by its beneficial microbiome selectivity, likely contributing to enhanced efficacy in difficult to treat bacterial infections and de-risking late stage studies.
Regulatory ProgressThe end-of-Phase 2 meeting with the FDA has completed with alignment reached on the Phase 3 program, indicating regulatory progress.
Bears Say
Cash ReservesThe company ended the quarter with approximately $5.9 million, which does not include $1.4 million from a recent warrant exercise.
Financial StandingAcurx reported a net loss of ($2.0M) for the third quarter, which might raise concerns about the company's financial standing.
Acurx Pharmaceuticals News
ACXP FAQ
What was Acurx Pharmaceuticals’s price range in the past 12 months?
Acurx Pharmaceuticals lowest stock price was $3.17 and its highest was $25.00 in the past 12 months.
What is Acurx Pharmaceuticals’s market cap?
Acurx Pharmaceuticals’s market cap is $10.03M.
When is Acurx Pharmaceuticals’s upcoming earnings report date?
Acurx Pharmaceuticals’s upcoming earnings report date is Mar 12, 2026 which is in 89 days.
How were Acurx Pharmaceuticals’s earnings last quarter?
Acurx Pharmaceuticals released its earnings results on Nov 12, 2025. The company reported -$1.23 earnings per share for the quarter, beating the consensus estimate of -$1.31 by $0.08.
Is Acurx Pharmaceuticals overvalued?
According to Wall Street analysts Acurx Pharmaceuticals’s price is currently Undervalued.
Does Acurx Pharmaceuticals pay dividends?
Acurx Pharmaceuticals does not currently pay dividends.
What is Acurx Pharmaceuticals’s EPS estimate?
Acurx Pharmaceuticals’s EPS estimate is -1.01.
How many shares outstanding does Acurx Pharmaceuticals have?
Acurx Pharmaceuticals has 2,081,323 shares outstanding.
What happened to Acurx Pharmaceuticals’s price movement after its last earnings report?
Acurx Pharmaceuticals reported an EPS of -$1.23 in its last earnings report, beating expectations of -$1.31. Following the earnings report the stock price went down -10.753%.
Which hedge fund is a major shareholder of Acurx Pharmaceuticals?
Currently, no hedge funds are holding shares in ACXP
Company Description
Acurx Pharmaceuticals
Acurx Pharmaceuticals (ACXP) is a clinical-stage biopharmaceutical company focused on developing new antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, the Centers for Disease Control and Prevention, and the Food and Drug Administration. The company's lead product candidate, ibezapolstat, is designed to address the growing challenge of antibiotic resistance, specifically targeting Clostridioides difficile infections. Acurx is committed to advancing its pipeline of novel antibiotic compounds to meet the critical need for new treatments in infectious disease care.
ACXP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mix of positive developments, such as achieving NASDAQ compliance, patent expansion, and successful presentations, alongside ongoing financial challenges and significant reductions in R&D expenses. The company's improved financial position and strategic scientific advancements were notable, though the net loss and reduced R&D spending highlight areas of concern.View all ACXP earnings summariesACXP Stock 12 Month Forecast
Average Price Target
$30.50
▲(642.09% Upside)
Technical Analysis
Ibio
―
Windtree Therapeutics
―
BioRestorative Therapies
―
Lixte Biotechnology Holdings
―
Bolt Biotherapeutics
―